Recent News

• 12.09.2025 - Akari Therapeutics Highlights Preclinical Data Demonstrating Therapeutic Potential of Lead Candidate, AKTX-101, for Hard-to-Treat K-Ras Mutant Pancreatic Cancer
• 12.04.2025 - Akari Therapeutics Provides Corporate Update and Highlights its ADC Payload Innovation Expected to Drive Value in New CEO Corner Segment
• 11.25.2025 - Akari Therapeutics Announces Release of the Next CEO Corner Segment
• 11.25.2025 - Akari Therapeutics Announces Release of the Next CEO Corner Segment
• 11.19.2025 - Notice of General Meeting of Shareholders (GM) to be held on December 15, 2025
• 11.18.2025 - Akari Therapeutics Appoints Biotech Finance Leader, Kameel D. Farag as Interim Chief Financial Officer
• 11.10.2025 - Akari Therapeutics Presents Promising Immuno-OncologyData for its Novel Splicing-Targeted ADC Payload Driving ImmuneActivation, Both as Single Agent and in Combination with Anti-PD1 Checkpoint Inhibitors
• 11.10.2025 - Akari Therapeutics Presents Promising Immuno-Oncology Data for its Novel Splicing-Targeted ADC Payload Driving Immune Activation, Both as Single Agent and in Combination with Anti-PD1 Checkpoint Inhibitors
• 11.04.2025 - Akari Therapeutics’ Accepted Abstract Showcasing its Novel Splicing-Targeted ADC Payload Driving Immune Activation Now Available
• 11.04.2025 - Akari Therapeutics’ Accepted Abstract Showcasing its Novel Splicing-Targeted ADC Payload Driving Immune Activation Now Available

Recent Filings

• 12.08.2025 - EX-99.1 EX-99.1
• 12.08.2025 - 8-K Current report
• 12.05.2025 - 424B3 Prospectus [Rule 424(b)(3)]
• 12.02.2025 - EFFECT Notice of Effectiveness
• 11.26.2025 - 8-K Current report
• 11.17.2025 - DEF 14A Other definitive proxy statements
• 11.17.2025 - S-1 General form for registration of securities under the Securities Act of 1933
• 11.13.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 11.07.2025 - PRE 14A Other preliminary proxy statements
• 11.04.2025 - 4 Statement of changes in beneficial ownership of securities